Skip to content

Portola Pharmaceuticals, Inc.

CIK 0001269021

← back to feed
Revenue (TTM)
$113.78M
+190.7% YoY Q1 May 2020
Net Income (TTM)
−$262.76M
−94.8% YoY Q1 May 2020
EPS Diluted (TTM)
−$8.71
−406.3% YoY Q1 May 2020
Gross Margin
83.2%
Q1 May 2020
Operating Margin
-210.6%
Q1 May 2020
Net Margin
-230.9%
Q1 May 2020
Free Cash Flow (TTM)
−$239.84M
Q1 May 2020
Cash
$196.24M
Q1 May 2020
Total Debt
$126.8M
Q1 May 2020
Shares Outstanding
78.48M sh
Q1 May 2020

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings